{
    "id": 401,
    "fullName": "KRAS wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type KRAS indicates that no mutation has been detected within the KRAS gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "wild-type",
    "createDate": "03/13/2014",
    "updateDate": "02/05/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10503,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in improved overall response rate, disease control rate, progression-free survival, and overall survival (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months,18.2 vs. 6.6 months, respectively) in pancreatic cancer patients without detectable KRAS mutations in circulating tumor DNA (PMID: 27975152).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 5545,
                "therapyName": "Gemcitabine + Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8575,
                    "pubMedId": 27975152,
                    "title": "Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27975152"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13923,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SYM004 treatment did not improve overall survival compared to standard of care in patients with metastatic colorectal cancer harboring no KRAS exon 2 mutations, and acquired resistance to anti-EGFR therapy (PMID: 29423521).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1454,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1775,
                "therapyName": "Panitumumab + Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1308,
                    "pubMedId": 24919569,
                    "title": "Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24919569"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11609,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination of Erbitux (cetuximab), Sprycel (dasatinib), and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma, with an overall response rate of 20% (6/30) in the Phase Ib portion, and 13% (3/24) in KRAS codon 12/13 wild-type patients in the Phase II portion (PMID: 28280091; NCT00501410).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 6074,
                "therapyName": "Cetuximab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + Dasatinib + FOLFOX"
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9667,
                    "pubMedId": 28280091,
                    "title": "Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28280091"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7711,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MISSION) trial, treatment with Nexavar (sorafenib) resulted in improved progression-free survival (PFS) in both KRAS-mutant (2.6 vs 1.7 mo, HR=0.46, p=0.007) and KRAS wild-type (2.7 vs 1.4 mo, HR=0.58, p<0.001) patients with non-small cell lung cancer when compared to placebo, however, overall survival (OS) was similar between the two arms, and biomarker treatment interaction analysis indicated no interaction between KRAS and PFS (p=0.696) or OS (p=0.743) (PMID: 26743856; NCT00863746).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 6454,
                    "pubMedId": 26743856,
                    "title": "Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743856"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1282,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, colorectal cancer patients treated with Avastin (bevacizumab) demonstrated improved objective response rate (54.8% vs 48.3%, OR=1.42, p=0.02), median progression-free survival (HR=0.85, p=0.02), and median overall survival (HR=0.65, p=0.01) in KRAS wild-type patients compared to KRAS mutant patients (PMID: 23828442).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 454,
                    "pubMedId": 23828442,
                    "title": "KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23828442"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11286,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9206,
                    "pubMedId": 28632865,
                    "title": "Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28632865"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11329,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS wild-type lung carcinoma cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5442,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, BBI608 and Vectibix (panitumumab) combination therapy resulted in PR in 22.2% (2/9), SD in 22.2% (2/9), and median PFS of 9 weeks in colorectal cancer patients carrying wild-type Kras naive for anti-EGFR therapy; compared to SD in 53.3% (8/15), and median PFS of 16.4 weeks in patients failed anti-EGFR treatment (J Clin Oncol 33, 2015 (suppl; abstr 3617)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2092,
                "therapyName": "Napabucasin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5055,
                    "pubMedId": null,
                    "title": "A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.",
                    "url": "http://meetinglibrary.asco.org/content/153568-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3686,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a PFS difference was not observed between KRAS wild-type biliary tract cancer patients when treated with a combination of Vectibix (panitumumab), Gemzar (gemcitabine), and Eloxatin (oxaliplatin) versus Gemzar (gemcitabine) and Eloxatin (oxaliplatin) only (PMID: 26540314).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3226,
                "therapyName": "Gemcitabine + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3992,
                    "pubMedId": 26540314,
                    "title": "Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26540314"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8150,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4647,
                "therapyName": "Cetuximab + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6559,
                    "pubMedId": 27458141,
                    "title": "A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27458141"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS wild-type colorectal cancer cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8151,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4647,
                "therapyName": "Cetuximab + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6559,
                    "pubMedId": 27458141,
                    "title": "A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27458141"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7859,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) treatment resulted in a greater survival benefit in non-small cell lung cancer patients with wild-type KRAS compared to treatment in those patients harboring KRAS mutations (PMID: 18626007).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6515,
                    "pubMedId": 18626007,
                    "title": "Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18626007"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6955,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538); NCT01001377).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5986,
                    "pubMedId": null,
                    "title": "Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.",
                    "url": "http://meetinglibrary.asco.org/content/165575-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 582,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Vectibix (panitumumab) demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS, resulting in a median progression-free survival of 12.3 weeks, compared to 7.3 weeks with best supportive care (BSC), improved overall survival (HR=0.67), and a response rate of 17% (21/141) (PMID: 18316791; NCT00113763).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 340,
                    "pubMedId": 18316791,
                    "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18316791"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5505,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191; NCT00113763).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5071,
                    "pubMedId": 23625191,
                    "title": "An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23625191"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4368,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3498,
                "therapyName": "Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin",
                "synonyms": "Necitumumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4508,
                    "pubMedId": 26766738,
                    "title": "Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3222,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 1749,
                "name": "squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 342,
                    "pubMedId": 23877793,
                    "title": "K\u2011ras gene mutation as a predictor of cancer cell responsiveness to metformin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23877793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12559,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Selumetinib (AZD6244) and Taxotere (docetaxel) did not result in a greater clinical benefit in KRAS wild-type patients with non-small cell lung carcinoma when compared to Taxotere (docetaxel) plus placebo (PMID: 29045535; NCT01750281).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1117,
                "therapyName": "Docetaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10431,
                    "pubMedId": 29045535,
                    "title": "SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045535"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3268,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3264,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4012,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 748,
                "therapyName": "GDC-0623",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4367,
                    "pubMedId": null,
                    "title": "A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/B75.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6964,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Cometriq (cabozantinib) and Vectibix (panitumumab) combination treatment resulted in a median progression free survival of 3.7 months, median overall survival of 7.5 months, and partial response in 14% (2/14) of KRAS wild-type colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 3548)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 1985,
                "therapyName": "Cabozantinib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5988,
                    "pubMedId": null,
                    "title": "Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).",
                    "url": "http://meetinglibrary.asco.org/content/166423-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3872,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS wild-type gastric adenocarcinoma in culture, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6954,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Avastin (bevacizumab) and Xeloda (capecitabine) maintenance treatment resulted in better time to first progression (HR = 0.27), time to second progression (HR = 0.42) and overall survival (HR = 0.64) in KRAS wild-type colorectal cancer patients compared to patients harboring KRAS mutations (HR = 0.40, 0.75, 1.07 respectively) (J Clin Oncol 34, 2016 (suppl; abstr 3525)).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2097,
                "therapyName": "Bevacizumab + Capecitabine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5985,
                    "pubMedId": null,
                    "title": "Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.",
                    "url": "http://meetinglibrary.asco.org/content/162510-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11333,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression in tumors, but had no effect on tumor growth in patient-derived xenograft models of KRAS wild-type non-small cell lung carcinoma (PMID: 28615361).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11285,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9206,
                    "pubMedId": 28632865,
                    "title": "Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28632865"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12580,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS wild-type colorectal cancer patients demonstrated a greater response to Erbitux (cetuximab) treatment compared to KRAS mutant colorectal cancer patients, including an objective response of 41% (27/66) vs. 0% (0/42), a median overall survival of 43 weeks vs. 27.3 weeks, and an overall survival of 74.9 weeks vs. 30.6 weeks, respectively (PMID: 17998284).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10457,
                    "pubMedId": 17998284,
                    "title": "KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17998284"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4013,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 748,
                "therapyName": "GDC-0623",
                "synonyms": null
            },
            "indication": {
                "id": 138,
                "name": "vaginal squamous tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4367,
                    "pubMedId": null,
                    "title": "A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/B75.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9100,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS wild-type pancreatic cancer cells were less sensitive to Aphanin induced growth inhibition and apoptosis in culture (PMID: 27333990).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4900,
                "therapyName": "Aphanin",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6915,
                    "pubMedId": 27333990,
                    "title": "Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7369,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3356,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3614,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 100% (2/2) of colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",
            "molecularProfile": {
                "id": 13841,
                "profileName": "AKT1 E17K BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3671,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) of KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",
            "molecularProfile": {
                "id": 14283,
                "profileName": "BRAF wild-type KRAS wild-type PIK3CA mut"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3873,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3373,
                "therapyName": "GA201 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16552,
                "profileName": "EGFR dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4944,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5563,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5108,
                    "pubMedId": 27002107,
                    "title": "Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002107"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5622,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",
            "molecularProfile": {
                "id": 21303,
                "profileName": "KRAS wild-type PIK3CA H1047R"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type colon cancer cells harboring BRAF V600E in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 21304,
                "profileName": "BRAF V600E KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5623,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",
            "molecularProfile": {
                "id": 21304,
                "profileName": "BRAF V600E KRAS wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6482,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",
            "molecularProfile": {
                "id": 23355,
                "profileName": "ERBB2 pos KRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5566,
                    "pubMedId": 27108243,
                    "title": "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27108243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7364,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25310,
                "profileName": "FGFR1 dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7431,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383).",
            "molecularProfile": {
                "id": 25455,
                "profileName": "CDKN2A loss KRAS wild-type"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11554,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, ATN1 mRNA level was decreased in the progressive disease group compared to the disease control group in KRAS and BRAF wild-type colorectal cancer patients treated with Erbitux (cetuximab) or Vectibix (panitumumab), which supported its potential role as a predictive marker for treatment response (PMID: 23098991).",
            "molecularProfile": {
                "id": 28143,
                "profileName": "ATN1 dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1100,
                    "pubMedId": 23098991,
                    "title": "MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23098991"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11553,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, ATN1 mRNA level was decreased in the progressive disease group compared to the disease control group in KRAS and BRAF wild-type colorectal cancer patients treated with Erbitux (cetuximab) or Vectibix (panitumumab), which supported its potential role as a predictive marker for treatment response (PMID: 23098991).",
            "molecularProfile": {
                "id": 28143,
                "profileName": "ATN1 dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1100,
                    "pubMedId": 23098991,
                    "title": "MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23098991"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28493,
                "profileName": "EGFR over exp KRAS wild-type"
            },
            "therapy": {
                "id": 6312,
                "therapyName": "Trametinib + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28493,
                "profileName": "EGFR over exp KRAS wild-type"
            },
            "therapy": {
                "id": 4482,
                "therapyName": "Afatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16424,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BMS-906024 and Taxol (paclitaxel) resulted in synergy in BRAF and KRAS wild-type non-small cell lung cancer (NSCLC) cell lines in culture, but not in cell lines harboring KRAS or BRAF activating mutations, and demonstrated enhanced tumor growth inhibition in cell line and patient-derived xenograft (PDX) models of BRAF, KRAS wild-type NSCLC (PMID: 28978720).",
            "molecularProfile": {
                "id": 28546,
                "profileName": "BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 8027,
                "therapyName": "BMS-906024 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14491,
                    "pubMedId": 28978720,
                    "title": "Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978720"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12189,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",
            "molecularProfile": {
                "id": 28546,
                "profileName": "BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15450,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BOND) that supported FDA approval, Erbitux (cetuximab) in combination with Camptosar (irinotecan) resulted in significantly improved response rate (22.9% vs 10.8%), median time to progression (4.1 vs 1.5 months) compared to monotherapy in patients with EGFR positive metastatic colorectal cancer refractory to irinotecan (PMID: 15269313).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13329,
                    "pubMedId": 15269313,
                    "title": "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15269313"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15448,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CA225-025) that supported FDA approval, Erbitux (cetuximab) treatment significantly improved overall survival (9.5 vs 4.8 months, HR=0.55, p<0.001) and progression-free survival (3.7 vs 1.9 months, HR=0.40, p<0.001) compared to supportive care in patients with EGFR-positive, KRAS wild-type colorectal cancer who were refractory or intolerant of chemotherapy (PMID: 18946061; NCT00079066).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13328,
                    "pubMedId": 18946061,
                    "title": "K-ras mutations and benefit from cetuximab in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18946061"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12581,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CRYSTAL) that supported FDA approval, the combination of Erbitux (cetuximab) and FOLFIRI resulted in improved progression-free survival (HR=0.68, p=0.02), progression-free survival (9.9 vs 8.7 months), and overall survival (HR=0.84) compared to FOLFIRI alone in patients with EGFR positive, KRAS wild-type colorectal cancer (PMID: 19339720; NCT00154102).",
            "molecularProfile": {
                "id": 28762,
                "profileName": "EGFR pos KRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10458,
                    "pubMedId": 19339720,
                    "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19339720"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16986,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17019,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17020,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17016,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2184,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFIRINOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16975,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 8360,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOXIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17017,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1986,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17029,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16490,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) and Camptosar (irinotecan) rechallenge resulted in a response rate of 21% (6/28, 6 partial responses) and a disease control rate of 54% (15/28) in RAS and BRAF wild-type colorectal cancer patients that acquired resistance to first-line cetuximab and irinotican-based therapy, patients with wild-type RAS in ctDNA at baseline achieved longer median progression-free survival (4.0 vs 1.9 mo, HR=0.44, p=0.03) compared to those with mutant RAS (PMID: 30476968; NCT02296203).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14554,
                    "pubMedId": 30476968,
                    "title": "Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30476968"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16985,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17023,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13278,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 6803,
                "therapyName": "Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + Bevacizumab + FOLFIRI "
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17030,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17022,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13276,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17024,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17018,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17015,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 8360,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOXIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1986,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16976,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2184,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFIRINOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15907,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a\u00a0patient with KRAS wild-type pancreatic ductal adenocarcinoma\u00a0harboring\u00a0an ATP1B1-NRG1 fusion had reduced\u00a0liver\u00a0metastases size at 7 weeks when treated with Gilotrif (afatinib), however, disease progression was evident\u00a0after\u00a03 months;\u00a0and\u00a0Gilotrif (afatinib) reduced AKT and ERK signaling in cultured pancreatic cells\u00a0expressing an\u00a0ATP1B1-NRG1 fusion (PMID: 29802158).",
            "molecularProfile": {
                "id": 31309,
                "profileName": "ATP1B1 - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18700,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in significant radiologic response and clinical improvement 4 weeks after initiation of therapy in a patient with KRAS wild-type pancreatic ductal adenocarcinoma harboring an ATP1B1-NRG1 fusion, however, his disease progressed at 5.5 months (PMID: 31068372).",
            "molecularProfile": {
                "id": 31309,
                "profileName": "ATP1B1 - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15909,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case\u00a0study,\u00a0a patient\u00a0with\u00a0KRAS wild-type pancreatic ductal adenocarcinoma\u00a0harboring\u00a0an APP-NRG1 fusion had stable disease and improved liver function after 12 weeks of\u00a0combined\u00a0Tarceva (erlotinib),\u00a0Herceptin (trastuzumab), Abraxane (nab-paclitaxel), Adrucil (5-fluorouracil), and Wellcovorin (leucovorin) therapy (PMID: 29802158).",
            "molecularProfile": {
                "id": 31310,
                "profileName": "APP - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 7804,
                "therapyName": "Erlotinib + Fluorouracil + Leucovorin + Nab-paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18705,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in significant radiologic response and resolution of metastasis 4 weeks after initiation of therapy in a patient with KRAS wild-type pancreatic ductal adenocarcinoma harboring an ATP1B1-NRG1 fusion, and he continued on treatment after 5 months (PMID: 31068372).",
            "molecularProfile": {
                "id": 31310,
                "profileName": "APP - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15908,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study,\u00a0a patient with KRAS wild-type pancreatic ductal adenocarcinoma\u00a0harboring\u00a0a SARAF-NRG1-CDH6 fusion had a partial remission of liver metastases when treated with combined\u00a0Tarceva (erlotinib) and\u00a0Perjeta (pertuzumab), but disease progression was observed after three months (PMID: 29802158).",
            "molecularProfile": {
                "id": 31464,
                "profileName": "NRG1 fusion KRAS wild-type"
            },
            "therapy": {
                "id": 7802,
                "therapyName": "Erlotinib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16101,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower EREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31534,
                "profileName": "BRAF wild-type EREG dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16099,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower EREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31534,
                "profileName": "BRAF wild-type EREG dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 1601,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16100,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16098,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1601,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ONO-7579 decreased NTRK2 phosphorylation and reduced migration, invasion, and proliferation of a gallbladder cell line expressing NTRK2 with wild-type KRAS in culture (PMID: 29599313).",
            "molecularProfile": {
                "id": 31607,
                "profileName": "KRAS wild-type NTRK2 pos"
            },
            "therapy": {
                "id": 8005,
                "therapyName": "ONO-7579",
                "synonyms": null
            },
            "indication": {
                "id": 3121,
                "name": "gallbladder cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14462,
                    "pubMedId": 29599313,
                    "title": "The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29599313"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16379,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis,\u00a017.6% (3/17)\u00a0of\u00a0colorectal cancer\u00a0patients\u00a0with wild-type KRAS who did not respond to treatment with either\u00a0Erbitux (cetuximab)\u00a0or\u00a0Vectibix (panitumumab)\u00a0were found to harbor ERBB2 (HER2) amplifications, while no patients in the KRAS wild-type\u00a0therapy-responsive cohort were found to have ERBB2 (HER2) amplification or\u00a0overexpression\u00a0(n=14) (PMID: 22586653).",
            "molecularProfile": {
                "id": 31619,
                "profileName": "ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16380,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis,\u00a017.6% (3/17)\u00a0of\u00a0colorectal cancer\u00a0patients\u00a0with wild-type KRAS who did not respond to treatment with either\u00a0Erbitux (cetuximab)\u00a0or\u00a0Vectibix (panitumumab)\u00a0were found to harbor ERBB2 (HER2) amplifications, while no patients in the KRAS wild-type\u00a0therapy-responsive cohort were found to have ERBB2 (HER2) amplification or\u00a0overexpression\u00a0(n=14) (PMID: 22586653).",
            "molecularProfile": {
                "id": 31619,
                "profileName": "ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16381,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) amplification was identified in 36% (4/11) of unique colorectal cancer patient-derived xenografts (PDX) resistant to Erbitux (cetuximab)\u00a0treatment\u00a0and wild-type for KRAS, BRAF, PIK3CA, and NRAS compared to 2 to 3%\u00a0(3/137, 3/112 in archival specimens)\u00a0in an unselected population (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16384,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in disease stabilization in one\u00a0model,\u00a0but was ineffective in\u00a0the second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16385,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Perjeta (pertuzumab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume for both\u00a0models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 5958,
                "therapyName": "Lapatinib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16383,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Erbitux (cetuximab) and Perjeta (pertuzumab) treatment of patient-derived xenograft (PDX) models with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in a brief delay of tumor growth\u00a0in one model\u00a0and disease stabilization in a second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 8015,
                "therapyName": "Cetuximab + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16386,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Erbitux (cetuximab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume\u00a0for both models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 1672,
                "therapyName": "Cetuximab + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16382,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study,\u00a0two\u00a0patient-derived xenograft\u00a0(PDX) models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA were resistant to Perjeta (pertuzumab) treatment (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Navitoclax (ABT-263) and YM-155 did not inhibit growth of colorectal cancer patient-derived xenografts with BCL2L1 wild-type and and KRAS wild-type (PMID: 28611106).",
            "molecularProfile": {
                "id": 32468,
                "profileName": "BCL2L1 wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 8445,
                "therapyName": "Navitoclax + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15327,
                    "pubMedId": 28611106,
                    "title": "A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19007,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type lung cancer cells harboring EGFR E746_A750del in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33810,
                "profileName": "EGFR E746_A750del KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type lung cancer cells harboring EML4-ALK in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33811,
                "profileName": "EML4 - ALK KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19009,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type colon cancer cells harboring TPM3-NTRK1 in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33812,
                "profileName": "TPM3 - NTRK1 KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16994,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and wild-type KRAS and BRAF (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16993,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and wild-type KRAS and BRAF (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16984,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and KRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16981,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and KRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 496,
            "profileName": "KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2364,
            "profileName": "BRAF wild-type KRAS wild-type MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13841,
            "profileName": "AKT1 E17K BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13842,
            "profileName": "BRAF wild-type KRAS wild-type PIK3CA R88Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14283,
            "profileName": "BRAF wild-type KRAS wild-type PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16552,
            "profileName": "EGFR dec exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19839,
            "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21303,
            "profileName": "KRAS wild-type PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21304,
            "profileName": "BRAF V600E KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23355,
            "profileName": "ERBB2 pos KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25310,
            "profileName": "FGFR1 dec exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25455,
            "profileName": "CDKN2A loss KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28143,
            "profileName": "ATN1 dec exp BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28493,
            "profileName": "EGFR over exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28546,
            "profileName": "BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28762,
            "profileName": "EGFR pos KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29053,
            "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31309,
            "profileName": "ATP1B1 - NRG1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31310,
            "profileName": "APP - NRG1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31311,
            "profileName": "SARAF - NRG1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31464,
            "profileName": "NRG1 fusion KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31499,
            "profileName": "BRAF wild-type EREG pos KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31500,
            "profileName": "AREG pos BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31533,
            "profileName": "AREG over exp BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31534,
            "profileName": "BRAF wild-type EREG dec exp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31535,
            "profileName": "AREG dec exp BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31607,
            "profileName": "KRAS wild-type NTRK2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31619,
            "profileName": "ERBB2 amp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31620,
            "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31649,
            "profileName": "BRAF V600E KRAS wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32468,
            "profileName": "BCL2L1 wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33810,
            "profileName": "EGFR E746_A750del KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33811,
            "profileName": "EML4 - ALK KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33812,
            "profileName": "TPM3 - NTRK1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35566,
            "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}